Zenlabs Ethica Q1 FY27 Results

Zenlabs Ethica reported a net loss of ₹0.57 crore for the quarter ended June 30, 2026, compared to a profit of ₹0.03 crore in the same period last year. The company's revenue from operations increased by 23.5% to ₹14.18 crore from ₹11.48 crore in Q1 FY26.

Reader Takeaway: Net loss in Q1 FY27, focus on expense management and stock trading.

What just happened

Zenlabs Ethica Ltd recorded a net loss of ₹0.57 crore (₹57.12 lakh) for the first quarter of FY27, ending June 30, 2026. This is a reversal from a profit of ₹0.03 crore (₹3.33 lakh) in the corresponding quarter of the previous fiscal year (Q1 FY26).

Why this matters

The shift from profit to loss signals pressure on the company's bottom line. Despite a healthy 23.5% increase in revenue from operations to ₹14.18 crore (₹1,417.66 lakh), total expenses at ₹14.73 crore (₹1,473.28 lakh) outpaced total income.

The backstory

The company primarily operates in the trading of pharmaceutical formulations. The current quarter's results show a significant impact from stock-in-trade adjustments and purchases, which were ₹4.76 crore and ₹8.78 crore, respectively.

What changes now

Investors will be looking for management's strategies to improve profitability. The company's ability to control expenses, particularly those related to stock-in-trade, will be crucial.

Risks to watch

The primary concern is the net loss, indicating that the cost of goods sold and operating expenses are exceeding revenue. High expenses, especially related to stock-in-trade, need careful management.

Peer comparison

As Zenlabs Ethica operates solely in trading pharmaceutical formulations, direct profit comparisons with manufacturing pharma companies can be misleading. However, within the trading segment, profitability relative to revenue and expense control will be key.

Context metrics (time-bound)

Revenue from operations for Q1 FY27 stood at ₹14.18 crore, up from ₹11.48 crore in Q1 FY26. The net loss for Q1 FY27 was ₹0.57 crore, contrasting with a net profit of ₹0.03 crore in Q1 FY26. Basic and diluted EPS was ₹(0.88).

What to track next

Investors should monitor Zenlabs Ethica's subsequent quarterly results, focusing on trends in revenue growth, expense management, and the company's ability to return to profitability.